Further statistical analysis revealed non-hotspot mutations within SETD2 (Fig. 1B) with missense mutations predominating in NSCLC, melanoma, and colorectal cancer, whereas truncating mutations predominated in renal cell carcinoma (Fig. 1C). This evidence concerns the gene SETD2 and melanoma.